Trela M, Nelson PN, Rylance PB. The role of molecular mimicry and other factors in the association of Human Endogenous Retroviruses and autoimmunity. APMIS 2016; 124: 88-104. Human Endogenous Retroviruses (HERVs) have been implicated in autoimmune and other diseases. Molecular mimicry has been postulated as a potential mechanism of autoimmunity. Exogenous viruses have also been reported to be associated with the same diseases, as have genetic and environmental factors. If molecular mimicry were to be shown to be an initiating mechanism of some autoimmune diseases, then therapeutic options of blocking antibodies and peptides might be of benefit in halting diseases at the outset. Bioinformatic and molecular modelling techniques have been employed to investigate molecular mimicry and the evidence for the association of HERVs and autoimmunity is reviewed. The most convincing evidence for molecular mimicry is in rheumatoid arthritis, where HERV K-10 shares amino acid sequences with IgG1Fc, a target for rheumatoid factor. Systemic lupus erythematosus is an example of a condition associated with several autoantibodies, and several endogenous and exogenous viruses have been reported to be associated with the disease. The lack of a clear link between one virus and this condition, and the spectrum of clinical manifestations, suggests that genetic, environmental and the inflammatory response to a virus or viruses might also be major factors in the pathogenesis of lupus and other autoimmune conditions. Where there are strong associations between a virus and an autoimmune condition, such as in hepatitis C and cryoglobulinaemia, the use of bioinformatics and molecular modelling can also be utilized to help to understand the role of molecular mimicry in how HERVs might trigger disease.
and endogenous viruses have been implicated (1, (4) (5) (6) . Of note is that all human cells possess a range of human endogenous retroviruses (HERVs), which since their discovery in the 1980s have been associated with autoimmune diseases and cancer (7) (8) (9) . In the field of autoimmunity there has been an interest to ascertain if HERVs provide a hidden danger to the instigation of certain autoimmune diseases and their progression when activated (10, 11) . This article describes the HERVs found in our genome together with regulatory units and highlights key HERVs which have been associated with particular autoimmune diseases. Study of exogenous viruses and immune-mediated diseases also helps our understanding of the mechanisms. In addition, potential mechanisms are highlighted but with particular emphasis on the role of molecular mimicry that may trigger and augment the disease process. Where relevant, the limitations of certain investigative procedures are shown.
HERVS IN THE HUMAN GENOME
The DNA of the human genome consists of 3 billion base pairs (bp) of which only 3% is credited for the formation of human proteins. In contrast, HERVs and solitary LTRs (long terminal repeats) constitute about 8% which contributes to the sum of retroviral elements found in our DNA (circa 45%); the remainder being classified as non-coding DNA ( Fig. 1) (12) . Far from being considered 'junk' DNA, the latter may have a role in the regulation of genes. HERVs are remnants of infectious retroviral agents that integrated into ancestral germline DNA (circa. 30-40 million years ago), expanded within the genome as retrotransposons and more latterly as infections agents, and have been inherited through successive human generations in a Mendelian fashion (13) . Thus, HERVs have been coined 'fossil' viruses and can be found on chromosomes as single or multicopy retroviral elements. Endogenous retroviruses have also been found in vertebrates and plants (14, 15) . Overall, HERVs are present in all human cells although their expression at the messenger RNA (mRNA) and protein level may greatly differ (16) . In general, HERVs show a similar although basic genomic format common to present day exogenous retroviruses such as the human immunodeficiency virus (HIV-1) and the human T-cell leukaemia virus (HTLV-I) in exhibiting three principal genes: group associated antigens (gag), polymerase (pol) and envelope (env), sandwiched between two regulatory LTRs, i.e., LTR-gag-pol-env-LTR ( Fig. 2) (17) . LTRs are sequences of DNA that are used by viruses to insert their genetic sequences into host genomes and contain promoter and enhancer regions. It is apparent that over time, a combination of sequence mutations, deletions and frame-shift errors in many HERVs have caused partial or whole genomic segments to have been lost to the extent that HERVs now exist as solitary long terminal repeats (LTRs) within our DNA. HERVs have been categorized into one of three classes based on similar morphological features to present day exogenous retroviruses: Class I (Gammaretroviruses), class II viruses (Betaretroviruses) and Class III viruses (Spumaviruses) (18) (Table 1) . Overall these classes represent approximately 2.8%, 0.3% and 4.6% of the approximate 100 000 + HE"RV/LTR transposable elements (12) . Moreover, phylogenetic analysis using molecular probes for the pol region highlight over 30 different HERV families, e.g., HERV-K, HERV-W, HERV-H. A complete database of HERVs can be found online (http://herv.img.cas.cz/). Of note is the HML-2 subfamily which represents the most prolific and active endogenous retrovirus in the human genome. Overall, it appears that some single and multicopy HERVs have the capacity to produce mRNA transcripts and products from intact open reading frames (ORF's) that are able to manufacture retroviral proteins and particles (19, 20) . Moreover, HERVs may exhibit polymorphism which may account for variation in background levels of expression between individuals (21).
HERVS ASSOCIATED WITH AUTOIMMUNE RHEUMATIC DISEASES AND OTHER CONDITIONS
The term autoimmunity relates to a phenomenon whereby the immune system, antibody (B cell) and/ or cytotoxic T cells mount an immune response to 'self' body components which can result in chronic unresolved inflammation and destruction of tissues and organs. There are over 80 different autoimmune disorders (systemic and organ specific), which have a global impact affecting over 100 million people (22) . Numerous elements are believed to contribute to the development of an auto-aggressive response including hereditary (HLA genes), gender, age, hormonal, and environmental factors (23) . In general, autoimmunity is prevented through central tolerance and apoptosis during the ontogeny of an individual's immune system and subsequently through peripheral tolerance (termed anergy) for those potentially autoreactive cells which enter the circulation. Molecular mimicry is considered a key mechanism in the loss of clonal anergy of B and T cells which could function alone, or alongside other mechanisms of cell activation, e.g., superantigen motifs, and gene modulation: altered gene expression and immune dysregulation, and the hypomethylation of 5-methylcytosine bases (epigenetics) (1, 18) . In addition, an infectious cause has LTRs: not only promote HERV expression but may also promote down-stream genes. gag: generating viral products which may contribute to autoantibody production. pol enzymes: facilitating viral infectivity. env: providing Env products contributing to autoantibody production and viral blockade. In addition, this region may generate an immunosuppressive peptide modulating immune-related cells and superantigens that may stimulate potential autoreactive T cells. A given HERV can also be influenced by host hormonal agents and external environmental factors (1, 18) . EBV may also transactivate HERV expression and directly promote autoreactive B-cell activity.
been implicated such as endogenous and exogenous virus and bacterial agents (24, 25) .
Over time, HERVs have been associated with rheumatological diseases through polymerase chain reaction (PCR) and serological studies (26, 27) . Initial PCR primers focused on the reverse transcriptase region to yield a 'fingerprint segment' of DNA that enabled the specificity of HERV to be identified; currently HERV-region specific primers are employed. Similarly, early serological studies used retroviral products, e.g., from HTLV-I, in enzyme linked immunosorbent assay (ELISA) and Westernblotting formats to ascertain antiviral reactivity that have gradually been replaced by particular HERV peptides and recombinant antigens. A consensus of potential HERVs in autoimmune diseases is presented in Table 2 . Moreover, particular HERVs have gained prominence in certain conditions, e.g., HERV-K10 in rheumatoid arthritis (RA), HRES-1 in systemic lupus erythematosus (SLE). Evidently, the particular role an endogenous virus might play will depend on the transcripts generated and the protein product(s) manufactured, e.g., for some viruses only Gag and/or Env products may yield antigenic capsid, or immunosuppressive peptide, superantigen motif, respectively ( Fig. 2) (28) .
HERV-K
Over 2500 HERV-K solo LTRs and approximately 91 full-length copies of HERV-K are found in human genome on multiple different chromosomes (29) . It is one of the most biologically active HERVs and its members retain open reading frames (ORFs) in gag, pol and env genes which encode viral products. While HERV-K proviruses have the potential to be expressed in healthy individuals, increased mRNA transcripts of HERV-K and IgG anti-HERV-K antibodies have been associated with autoimmunity, cancers, such as breast and prostate, as well as neurological conditions (Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Schizophrenia) (8, 30, 31) . In RA, antibodies to HERV-K10 Gag (HML-2 subgroup) have been shown to be significantly elevated as compared to healthy control subjects and non-immunological patients with osteoarthritis, and patients with inflammatory bowel disease (31) . HERV-K18 mRNA levels have also been reported to be enhanced in peripheral blood mononuclear cells and inflammatory lesions of patients with insulindependent diabetes mellitus (IDDM) (8) while HERV-K18.3 appears to increase the risk of multiple sclerosis (MS) by three-fold among individuals homozygous for this allele (25) . HERV-K18 has also been found to be elevated in Juvenile Idiopathic Arthritis (32) and other investigators found a greater prevalence of a more recently defined and relatively young virus HERV-K113, among RA and SLE patients (33, 34) . Other recently defined viruses include HERV-K111 and HERV-K105; the latter considered a variant of HERV-K111 from sequence analysis (35) . The biological effects of HERV-K111 remain unknown and most of its proteins are inactive due to mutagenesis. However, this virus encodes an Np9 accessory protein (putative oncogene) that might link it to the development of cancer. HERV-K111 is also transactivated by HIV-1 (36) . Moreover, it has been noted that some HIV-1-infected individuals show high levels of HERV-K RNA, DNA, protein and viral particles in their plasma (37) . A question remains whether, viruses in particular within the HERV-K family, re-acquire infectivity. While no infectious agent has been found in vivo, a reconstructed HERV-K (HML-2) viral genome has been generated from several complete but defective proviruses in vitro and was observed to produce infectious retroviral particles (38) . Consequently, there always remains the remote possibility of generating a potential infectious HERV-K viral agent through viral complementation.
HERV-Fc1
HERV-Fc1 is located on chromosome X together with HERV-S family (39) . HERV-Fc1 gag and env genes are complete and a substantial increase in extracellular gag RNA titres of this virus has been reported in patients with active MS (40) .
HERV-H
HERV-H located on chromosome 22q12, is one of the most abundant HERVs in human genome (41) . HERV-H retroviral particles have been detected in the plasma of MS patients together with reactivity to Env epitopes (8) . HERV-H has been found transcriptionally active in brain tissue in addition to placenta, spleen, skeletal muscle, thymus as well as in certain cancers (42, 43) .
HERV-R
HERV-R a key member, ERV-3 is a single-copy, full-length provirus with a long open reading frame (ORF) in the env region and functional LTRs located on chromosome 7. Again molecular mimicry between ERV-3 Env and several SLE autoantigens: Ribosomal-P, Ro/SS-A-ribonuclearprotein and Beta-2-glycoprotein have been demonstrated Table 2 highlights key HERVs that have largely been implicated in rheumatoid diseases mainly through serological and molecular studies. (44) . Of note, Beta-2-glycoprotein is associated with anti-phospholipid syndrome, while Ribosomal-P antibodies are strongly associated with neuropsychiatric SLE.
HERV-W
This family consists of approximately 650 elements distributed within the human genome. The locus ERVW-1 on chromosome 7q21.2, provides a fulllength proviral HERV-W copy with an env ORF that encodes Syncytin-1. Antibodies to Syncityn-1 have been found in MS patients and antibodies to HERV-W env peptides (NPSCPGGLGVTVCWTY and NSQCIRWVTPPTQIV) from MS patients also confirm reactivity to this virus (45) . A copy of ERVW-2 (Syncytin-2; HERV-FRD) in chromosome Xq22.3 could partially explain the higher prevalence of MS in women than in men (2:1 ratio). MSRV (MS associated retrovirus), has also been linked to the pathogenesis of this disease through the activation of innate immunity and superantigen since the full-length Env protein is expected to be expressed at the cell surface. MSRV transcript levels are increased in samples of cerebral spinal fluid and B lymphocytes from MS patients.
HERV-E
Over 1300 HERV-E elements have been observed in human genome and their integration has occurred in several waves. HERV-E elements are distributed within the genome as HERV-E gag, pol, env, solitary LTRs, or full length and mutated HERV-E fragments, e.g., clone 4-1. The latter is located on chromosome 19p12 and contains multiple deletions which prevent it from forming infectious viral particles. It can however encode p30gag and p15env proteins. Enhanced expression of mRNA from clone 4-1 was observed in T cells from SLE patients and salivary glands from patients with Sj€ ogren's syndrome. Serum antibodies to Gag products have also been reported in 50% of SLE patients (8) . In addition, antibodies to p30gag appear to crossreact with two nuclear autoantigens (U1-RNP and Sm) in samples of patients with SLE, Sj€ ogren's syndrome, and mixed connective tissue disease (46) .
HRES-1
Human T-cell lymphotropic virus (HTLV)-related endogenous sequence is located at chromosomal position 1q42 which possesses a number of disease susceptibility genes that predispose to SLE (47) (48) (49) . The genome of HRES-1 contains a single 5 0 LTR and a gag nucleotide sequence for which the former possesses 6 HRES-1 haplotypes with alleles that are associated with clinical manifestations of SLE, e.g., the presence of renal disease and absence of lung disease, and anti-phospholipid syndrome (50) . Thus, activation of HRES-1 and polymorphism within the genome may cause disease in some individuals but not others. Two Gag related products are generated: a 28-kD nuclear autoantigen (p28) and a 24-kD small GTP-ase (termed HRES-1/ Rab4). Studies undertaken have shown higher titres of auto-antibodies to HRES-1/p28 nuclear protein or synthetic peptides in patients with SLE who are more likely to have clinically active disease. Molecular mimicry may also be responsible in generating cross-reactive antibodies to HRES-1/p28 and the 70-kD spliceosomal protein U1 snRNP (51) (52) (53) . Preliminary data from our group also show molecular mimicry between HRES-1 Gag protein with U1 snRNP plus other autoantigens associated with SLE (54) . In lupus patients, CD4+ T cells appear to over-express HRES-1/Rab4 which regulates the recycling of CD4. Depletion of the latter, may contribute to abnormal T-cell activation and provide another mechanism for this HERV in SLE (55).
Human intracisternal A-type retroviral particles (HIAPs)
Antibodies to HIAPs that are antigenically related to HIV-1 have been detected in SLE patients and in Sj€ ogren's syndrome (56) . Importantly, HIAPs can modulate apoptosis prolonging self/foreign complexes which may augment autoimmunity (57, 58) .
LONG TERMINAL REPEATS
Solitary LTRs and LTRs with partial or complete retroviral sequences may have potential detrimental roles (59), or even functions that provide host benefit such as in human placental development (60) ( Table 3 ). In essence, this is because some LTRs harbour promoters and enhancers which can function in promoting mRNA synthesis of nearby host genes (61) or genes 70-100 kb away. For example, HERV-K10 has an integration site within the complement C2 gene, which in theory could lead to misactivation of the complement system. Moreover, both MHC Class I and II gene complexes possess a high density of HERV genes (62, 63) . LTRs may also possess hormone responsive elements which may influence HERV expression as demonstrated using cell lines harbouring HERV-K10 and stimulated with oestrogen and progesterone (64) . In addition, LTRs may provide alternative splice sites for protein products (60) .
SYNERGY BETWEEN HERVS AND OTHER VIRUSES
While HERVs have been implicated in certain autoimmune diseases, a variety of exogenous viruses have also been associated such as EpsteinBarr virus (EBV), in RA and SLE (65) (66) (67) , parvovirus B19 in RA (68) and hepatitis C in RA (69) . Moreover, DNA and viral particles of human cytomegalovirus (CMV) have been reported in synovial tissue and fluid from 10-50% of individuals with RA while chronic antigenic stimulation by hepatitis C virus has been regarded a key process in maintaining the proliferation of RF-producing B-cell clones (25) . Herpes viruses such as EBV and CMV have also been shown to influence HERV-K10 activity and upregulate (transactivate) HERV transcription (i.e., the notion of 'helper' virus) (31, 70) . Indeed transfection of plasmids encoding EBV gene products, EBNA-1, LMP1, and LMP2A, significantly enhance HERV-K10 transcripts. EBV also influences an HERV-18 superantigen motif in IDDM. Clearly, the Epstein-Barr virus can infect, remain in an opportune latent state but overall is a strong polyclonal B-cell activator which may stimulate bystander cells to help break tolerance. Consequently, a synergistic relationship may exist between HERVs and other exogenous viruses to mediate their effects (71) .
BIOINFORMATICS
The discipline known as bioinformatics entails the use of computer software for acquisition, organization, and examination of biological data (72) . It exists at the interface of molecular biology, information science, clinical medicine, and mathematics. Bioinformatics evolved rapidly in 1990s thanks to automated DNA sequencing and the Human Genome project. One of the key applications in bioinformatics is sequence similarity searches such as BLAST of a database, e.g., GenBank, the National Centre for Biological Information, NCBI (www.ncbi.nlm.nih/) which permits the identification of DNA or protein sequences that are similar to a query sequence. Global and local alignments rely on algorithms which calculate the best alignment of two sequences: the former comparing two sequences in their entirety while the latter searching for the best matching subsequences in the two query sequences (73) . Matrices such as BLOSUM (BLOck SUbstitution Matrix), BLOSUM62, are then employed to score pairs of aligned residues (77) . Protein sequences are generated from 20 naturally occurring amino acids and evolve under strong functional constraints so that any alterations in these sequences are strictly controlled due to their potentially deleterious effect. As a result, changes between amino acids (point mutations) usually involve substitutions between residues with similar properties which do not typically affect protein function or structure. Thus, substitution score matrices have been developed to show scores for amino acid substitutions. Tudos and co-workers (78) generated a residue replacement score for all amino acid pairs such that the larger the correlation (higher positive value), the greater the similarity of the amino acids. As a result, this parameter permits the identification of homology between protein sequences that would otherwise be disregarded (72) .
Bioinformatic programmes also enable 'in silico' analysis of antigenic 'hot spots' (amino acid peptides) of proteins. B-cell epitope prediction using biocomputing online software programmes (http:// www.expasy.ch/cgi-bin/protscale.pl) is largely focused on physico-chemical properties of an antigen which may be identified by antibodies (e.g., hydrophilicity, solvent accessibility, surface exposure, polarity). Here, established thresholds for predicting antigenic epitopes can be used or modified. Alongside bioinformatics, molecular modelling has enabled the visualization of epitopes and potential molecular mimics. This is exemplified through molecular graphics images generated using PyMOL (Molecular Graphics System, Version 1.2r3pre, Schrodinger, LLC: http://www.pymol.org/pymol) and enhanced using UCSF Chimera (Resource for Biocomputing, Visualization and Informatics, University of California, San Francisco, USA: http://www.cgl.ucsf.edu/chimera).
MOLECULAR MIMICRY
The premise of molecular mimicry is that microbial agent may share homology in amino acid sequence, or a structural motif, with human proteins (79) . As a consequence, an immune response to a given microbial antigenic determinant (epitope) could also induce undesired B-and T-cell immunity to a host protein. In effect, collateral damage may occur and have the potential to trigger autoimmunity with the concomitant breakdown of tolerance to self-components (18, 80) . In essence, the sequence similarity between microbial antigens and host-proteins must be close enough to share immunogenic determinants but adequately distant to be identified as foreign by the host's immune response.
A classical example of post-infectious autoimmunity due to molecular mimicry has been associated with the infection by gram-positive bacteria Streptococcus pyogenes which induces acute rheumatic fever following upper respiratory tract infection (81) . Host antibodies which target the bacterium's carbohydrate epitope (N-acetyl-b-D-glucosamine) and a virulence factor (M protein), cross-react with cardiac myosin, vimentin, and laminin in cardiac valves causing heart dysfunction (24). Moreover, increased levels of anti-myosin antibodies from sera of patients with rheumatic fever have been reported to cross-react with the M protein and carbohydrate antigens (25) . Post-infectious glomerulonephritis also highlights autoimmune damage resulting from an antibody response to exotoxins from Streptococcus and Staphylococcus and crossreactivity with protein mimics in glomeruli (82) .
Viral microbial agents have also been reported to share sequence and structural homology with host proteins. Monoclonal antibodies against DNA and RNA viruses which frequently afflict humans (herpes-, vaccinia, myxo-, paramyxo-, arena-, flavialpha-, rhabdo-, corona-, and retroviruses) have been reported to be crossreactive with host proteins, e.g., measles virus phosphoprotein with cytokeratin, herpes simplex virus type I with vimentin (79) . Parvovirus B19 capsid protein VP1 also shares homology with human cytokeratin and chronic parvovirus B19 infection can stimulate antiviral antibodies which crossreact with collagen type II: a key autoantigen in RA. Coxsackie B4 enterovirus is believed to play a role in pathogenesis of type I diabetes and its immunogenic viral capsid protein shares sequence homology with the pancreatic islet enzyme tyrosine phosphatase IA-2 (82) . Crossreactivity occurs also between amino acids of the acetylcholine receptor (AChR; a-subunit), targeted in myasthenia gravis (MG), with glycoprotein D on herpes simplex virus that suggests a viral contribution to MG pathogenesis (83) . Furthermore, Epstein-Barr virus has been reported as possible agent in SLE pathogenesis through molecular mimicry: a common autoantigen in SLE patients, Sm B' (PPPGMRPP) crossreacts with sequences from viral protein EBNA-1 (PPPGRRP) (84) .
It should be appreciated that similar or identical peptide segments can be found within and between human proteins and microbial agents that in effect remain immunologically inert. Thus not all such sequences may lead to molecular mimicry. The question is what makes a segment dangerous to induce disease and help break tolerance in certain individuals. The answer is likely to be multifactorial involving peptide presentation by antigen-presenting cells (APC), hence involving given MHC/HLA types, to initiate an immune response; evidently none would be provided if there were a 'hole' in the immunological repertoire for B and T cells. The autoantibodies may also play a part in the process of molecular mimicry and ensuing pathological damage by exhibiting reactivity to a continual source of peptide mimic that eventually induces isotype switching and affinity maturation (85) . This in turn would help to recruit additional components of the immune system, e.g., complement, other inflammatory cells. Antibodies in general may recognise a linear epitope of between 5 to 8 amino acids and discriminate between conformational epitopes differing by one or two residues (86) . Thus to some extent, the relative size of an epitope may be of significance. Binomial expansion of 20 n (20, total number of amino acids; n, number of residues) provides a probability of identical residues in different linear peptide chains of 2, 3, 4, 5, and 6 amino acids in length, as 1 in 400, 8000, 160 000, 3.2 million and 64 million, respectively. This highlights that homologous peptide segments of five amino acids or more are 'rare events', while homologies of 2/3 linear residues between two proteins are more likely to be found in nature. It is plausible that the latter epitopes may fall below the threshold of generating an immune response ('immunological escape') and should be treated with caution when evaluating alignment searches between host proteins and microbes. In inducing molecular mimicry, it is also likely that conservative amino acid substitutions within a peptide mimic plus residues in its local environment may provide the subtle difference to generate antibody reactivity. An isotype study using multiple antigenic peptide to generate antibodies, highlighted immunoglobulins that were predominantly IgM (87) . It was concluded that the peptide did not stimulate T cells to afford the necessary cytokines to switch isotype, e.g., to IgG. This indicates that a 'successful' peptide mimic must also stimulate T-helper cells in the disease process. Intriguingly cross-reactivity between a given microbe and host protein may also be facilitated by the degeneracy of antigen recognition by the T-cell receptor (81) .
HERV-K10 AND RHEUMATOID ARTHRITIS
HERV-K10, classified within the HML-2 family, has been implicated as a potential trigger of autoimmunity in RA through molecular mimicry (11, 18) . Both serological and molecular studies have shown increased reactivity to HERV-K10 Gag products (64) while a real-time PCR assay demonstrated upregulation of HERV-K10 mRNA in peripheral blood monocytes and synovium fibroblasts from RA patients (31) . Subsequent bioinformatic analysis that included hydrophilicity, accessibility, polarity, and flexibility of the Gag matrix protein, identified a 15 amino acid sequence that was likely to be highly antigenic. Indeed RA patients exhibited significant anti-IgG reactivity to this peptide containing the viral segment GKELK. Importantly, alignment analysis showed a similar sequence in the IgG1Fc fragment (GKEYK) which possessed positive Kudos scores for amino acid substitutions and constituted a key target for rheumatoid factor (RF) (85) . Hence, the autoimmune response in this situation could be mediated through molecular mimicry due to sequence similarity between the viral matrix peptide and IgG1Fc. It needs to be determined whether there is a correlation of immune response to HERV K-10 and disease activity and the effect of disease modifying drugs, to whether various therapies alter viral expression as well as suppressing the inflammatory response. Whether there is a difference in HERV expression between RF positive and RF negative patients also needs to be ascertained as well as additional potential epitopes that may elicit an autoimmune response in RA. More latterly, a novel peptide segment KVSTKNI was found on HERV-K10 Gag whereupon local alignment analysis identified a similar amino acid sequence, KVSNKAL on IgG1Fc (85). Intriguingly, both peptide mimics on IgG1Fc were separated by a single amino acid whereas the equivalent mimics on HERV-K10 were reversed in order of sequence position and displaced by circa 28 amino acids. It is also not known whether single or a combination of viral epitopes might be the immune trigger, and this needs to be determined before blocking peptides or antibodies to these viral peptide sequences are developed as potential therapeutic agents. However, the degree of evidence for the close association of HERV K-10 and RA possibly makes this a more likely therapeutic option than with other autoimmune diseases to which several viruses, both endogenous and exogenous, have been closely affiliated.
HERVS AND SYSTEMIC LUPUS ERYTHEMATOSUS
Epidemiological studies in SLE have shown a number of viral associations, both endogenous and exogenous. The HERV HRES-1 (47-54) and EBV (84) have most commonly been associated with lupus, but there is no clinical consensus as yet to a predominant viral association in the pathogenesis (1).
Preliminary studies in our laboratory have shown potential pathogenic links between lupus and HERV K-10, ERV-3, and HRES-1. Antibodies to HERV K-10 were demonstrated in some patients with lupus (88), although it is not clear whether HERV K-10 is a significant aetiological factor. However, there can be similarities in the arthritis of lupus and rheumatoid arthritis where the association of HERV-K10 is strongest (1) . Molecular mimicry between ERV-3 env protein and a number of lupus autoantigens plus collagen type IV has been observed. Amino acid substitutions appeared not to alter the conformational similarity between ERV-3 protein and the structure of protein epitopes as demonstrated through molecular modelling (89, 90) . Homology between HRES-1 Gag protein and nine SLE autoantigens (SmD1, SmN, La/SSB, Ribosome P, Ribosome P0, SnRNP BB', antiU1 RNP, Ro/SSA60, Histone H2B) has also been shown with protein conformations between viral protein and autoantigens being very similar, e.g., HRES-1 gag (EAVAGRGR) and SmD1 (EAGAGRVR). Interestingly, homology of amino acid sequences between lupus autoantigens has also been demonstrated (1, 54) although these preliminary observations need to be treated with caution.
It is an attractive proposition that a specific HERV epitope(s) might mimic particular autoantigens and thus help to explain the spectrum of systemic manifestations in lupus and the five histological types of glomerular disease with immune complex deposition. However, the number of autoantibodies associated with lupus, and the lack of selectivity and specificity of these autoantibodies could make this postulate too simplistic; genetic and environmental factors may be equally or more relevant.
In lupus and other autoimmune conditions the epidemiological associations with several exogenous and endogenous viruses, makes the pathogenic link of a specific infective organism to a particular condition through molecular mimicry difficult to prove. It may well be that in many, if not most cases where infections are associated with immune-related diseases, the immune response to the infection is part of 'multi-hit' aetiology.
EXOGENOUS AND ENDOGENOUS VIRUSES ASSOCIATED WITH IMMUNE-MEDIATED RENAL DISEASES
It is a clinical observation that a number of renal diseases can be triggered by intercurrent infections, either viral, or bacterial. The study of these conditions might reinforce evidence for a link between infections and autoimmunity and help the understanding of mechanisms as to how HERVs might cause autoimmunity through molecular mimicry. Alternatively an immune-mediated inflammatory response to an exogenous or endogenous virus could augment other genetic or environmental predisposing factors.
Renal diseases that appear to be sometimes triggered by infections include nephrotic syndrome due to minimal change nephropathy, IgA nephropathy and Henoch-Schonlein disease. However, there is no evidence that any of these conditions are associated with HERVs. Although IgA nephropathy and Henoch-Schonlein disease are characterized by immune deposits of IgA, minimal change has no glomerular immune complex deposition. Membranous nephropathy is characterized by immune complex deposition along the basement membrane, and most commonly is classified as 'idiopathic'. Less commonly the condition has been reported as being associated with secondary causes including a number of viral, bacterial, and parasitic infections. Primary membranous nephropathy is associated with the presence of antibodies against M-type phospholipase A2 receptor (PLA2R) and a genetic predisposition has been suggested. However, there appears to be no identified infective link in primary membranous nephropathy.
There are some clear examples of molecular mimicry between bacterial exotoxins and glomerular proteins in streptococcal and staphylococcal post-infectious glomerulonephritis (82) . Mimicry with a bacterial protein has been suggested in the pathogenesis of rapidly progressive glomerulonephritis (RPGN) in anti-neutrophil cytoplasmic antibody (ANCA) negative vasculitis (91) but this has not achieved general acceptance and no glomerular immune complexes are present. In contrast, the RPGN in Goodpasture's syndrome has a clear pathogenesis from antibodies to the glomerular basement membrane, but as a result of environmental rather than infective factors.
In HIV infection, the HIV genome can remain latent in the host cell genome. Consequently, it is of interest that in HIV a number of autoimmune and inflammatory rheumatic diseases occur, despite patients with HIV being immunocompromized. Immune thrombocytopaenia (ITP) also occurs in HIV. Cytokine production is thought to be responsible for the autoimmune and rheumatic conditions in HIV, but molecular mimicry between HIV and host antigen may also have role in pathogenesis (92) . Moreover, the expression of viral genes, together with a genetic susceptibility might predispose to HIV-associated nephropathy (HIVAN), one of the renal pathologies associated with HIV. HIVAN is a collapsing glomerulonephropathy, but without immune complex deposition (93) .
THE ASSOCIATION BETWEEN HEPATITIS C AND RHEUMATOID FACTOR IN MIXED CRYOGLOBULINAEMIA
The bioinformatic and molecular modelling techniques used in investigating the association of HERVs and rheumatoid arthritis (1, 18, 85) can be used in other autoimmune conditions that may be triggered by infections including exogenous and endogenous viruses. Cryoglobulinaemias are multisystem conditions associated with circulating cryoglobulins and are classified into Types I, II, and III. Type II mixed cryoglobulinaemia is a rare but intriguing condition where molecular mimicry would seem to be a strong possibility. The pathogenesis is poorly understood but the condition has been shown to be associated with the presence of viruses, particularly hepatitis C virus (HCV) infection, which occurs in up to 90% of cases. Hepatitis B and HIV infections have also been associated, albeit to a lesser extent (94) . It can present with a cutaneous vasculitic rash, a membranoproliferative glomerulonephritis and peripheral nerve involvement.
In mixed cryoglobulinaemia, circulating cryoglobulins contain polyclonal IgG and a monoclonal IgM Rheumatoid Factor, directed against IgG. Renal biopsies show subendothelial immune complex deposits which contain IgM, and the presence of HCV antigens in immune complexes has also been reported (95) . This evidence suggests this is a condition where there could be a pathologic link between a virus (HCV) and an autoantigen (Rheumatoid Factor). This disease could be considered to be a model for other autoimmune conditions and investigating these associations might help to give an insight into the pathogenesis of HERVs and autoimmunity, particularly as HERV K-10 provides a molecular mimic of rheumatoid factor (85) .
As a preliminary study, we utilized bioinformatic analysis and molecular modelling to investigate whether molecular mimicry might explain the association of HCV and Rheumatoid Factor in the pathogenesis of type II mixed cryoglobulinaemia (Fig. 3) .
The position of amino acid sequences in IgG1Fc that showed molecular mimicry between HCV and IgG1Fc were compared with the position of predicated Rheumatoid factor epitopes and immunodominant amino acids, which are likely to be antigenic sites (14) . Bioinformatic analysis of Hepatitis C and IgG1Fc revealed three potential regions of amino acid sequence homology with IgG1Fc, which were 5 or 6 amino acids in length, albeit with 1 or 2 amino acid substitutions (Fig. 3A) . Amino acid substitutions had high positive replacement scores, suggesting little effect on peptide conformation. All three peptides were located within the C H 2 or C H 3 domains of IgG1Fc, containing key regions for Rheumatoid Factor antibodies. Molecular modelling showed the single amino acid substitution in FNWAV produced only minor change in peptide conformation (Fig. 3B) . The FNWAV sequence was located in the C H 3 domain and was fully within a known epitope binding site for Rheumatoid Factor antibodies, and thus likely to be a potential molecular mimic. The PPLLES conformation was also little changed and was partly within a Rheumatoid Factor epitope in C H 3 domain, and within a major antigenic site. In contrast, for the PPIPPP sequence, amino acid substitutions significantly changed the molecular conformation, and it was only adjacent to an antigenic site.
Overall, molecular mimicry between HCV and the target for Rheumatoid Factor on IgG1Fc appears to have been demonstrated, which gives the potential for cross-reacting antigenic determinants being involved in the pathogenesis of type II mixed cryoglobulinaemia. The proposal is reinforced by the regions of homology being in domains of known antigenic sites on C H 2 and C H 3 region of IgG1Fc. Hence, it is postulated that key HCV epitopes, as molecular mimics of Rheumatoid factor, might also bind to IgG1Fc, and could contribute to the pathogenesis of cryoglobulins and immune complexes. The reported presence of Hepatitis B or HIV in some patients with cryoglobulinaemia does not necessarily imply a contribution to the disease, but could result from co-infection of viruses in an at-risk person. As Hepatitis B and HIV are also associated with immune-mediated conditions, their contributing to the pathogenesis of cryoglobulinaemia cannot be ruled out. It needs to be determined whether patients with mixed cryoglobulinaemia, and also rheumatoid arthritis, have alterations in amino acid sequences in the IgG1Fc region that predispose to the binding of Rheumatoid Factor.
CONCLUSION
Over the past two decades, there has been mounting evidence from various research groups for HERVs being involved in the pathogenesis of autoimmunity. While all humans carry HERV DNA, overall, these retroviruses have shown to have an increased expression in patients with autoimmune conditions as compared to healthy individuals and other disease controls. However, the evidence to assign a particular HERV to a single autoimmune disease or particular phenotypes is still lacking in most conditions, since several endogenous and exogenous viruses commonly have been reported to be associated with the same autoimmune condition. The evidence for the development of rheumatoid arthritis being mediated through molecular mimicry with HERV K-10 is perhaps stronger (31, 85) . Investigation of autoimmune conditions where the association of an exogenous virus and the disease is more prominent, such as in Hepatitis C and cryoglobulinaemia, may help us understand more of how HERVs might induce autoimmunity. It is possible that more than one endogenous or exogenous virus may interact, and the contribution of genetic predisposition and environmental factors also needs to be ascertained for each autoimmune condition. Clearly, the potential role of HERVs in the triggering and augmenting autoimmune diseases is part of a highly complex process including the breakdown of tolerance, HLA type and dysfunction of immune cells.
As the presence of HERV DNA is endemic in humans, multicentre studies are needed, ideally within and between different countries and ethnic groups, to look at patterns of expression of HERVs. Importantly, an evaluation of HERVs in healthy subjects needs to be undertaken to ascertain a database of 'basal levels' of HERV expression within given populations, over and above which HERVs might cause or contribute to the development of autoimmune diseases. Moreover, there needs to be standardization of laboratory techniques, methodology and reagents. At present, these appear to vary between different studies. Overall, this work may facilitate the identification of key HERVs associated with specific autoimmune diseases, and together with animal models and longitudinal studies of patients, should enhance our understanding of these viruses. If such links are clarified, then this should allow the development and testing of potential blocking proteins or antibodies. Hopefully the next decade will fully address the role of these 'hidden viruses': innocuous to some but a danger to others when activated. 
